期刊文献+

糖原累积病Ⅱ型的临床分析和基因学检测 被引量:12

Clinical and genomic study of the infant with glycogen storage disease typeⅡ
下载PDF
导出
摘要 目的探讨糖原累积病Ⅱ型的酶学诊断方法,并在中国人中进行基因突变分析。方法对1例临床表现为婴儿型糖原累积病Ⅱ型的8个月男性患儿进行研究,采用荧光分光光度计检测外周血白细胞酸性α#葡萄糖苷酶(GAA)活性,并采用16对引物对该家系GAA基因从外显子2到外显子20的编码区进行扩增并进行测序分析。结果该患儿白细胞GAA活性仅为18.72nmol/(mgprotein·hr),正常对照组为(130.5±86.7)nmol/(mgprotein·hr);基因学分析发现该患儿存在2个杂合突变位点,其中之一为1935位点C→A错义突变,是中国人最常见的突变位点,另外一个为988位点T→G错义突变,该位点为新发现突变位点。结论糖原累积病Ⅱ型是由于GAA基因突变引起GAA活性降低所致,酶活性检测和基因检测是目前最有效和可靠的诊断方法。 Objectives To investigate the biochemical diagnostic method of glycogen storage disease type Ⅱ (GSD Ⅱ ) and the gene mutations in an Chinese infant with this disease. Methods One 8 month-old boy presented as infantile type of GSD Ⅱ was studied. Acid alpha-D-glucosidase (GAA) activity in the peripheral blood leucocytes was measured using a fluorescence mieroplate reader to confirm the diagnosis. Sixteen pairs of intronie oligonucleotide primer were used to amplify the coding regions of GAA gene from exon 2 to exon 20 in the family members. The coding regions were sequenced both in the sense and antisense strands. Results The leukocytes GAA activity in this infant (18.72 nmol/(mg protein· hr)) was considerably lower than that in normal controls (130.5 ± 86.7 nmol/(mg protein· hr)). Genomic DNA sequencing revealed that the patient was heterozygous for 2 missense mutations. One allele con- rained the C1935A transversion which was the commonest mutation in Chinese patients,with the other containing a novel mutation of the T988G transversion. Conclusions GSD Ⅱ is caused by the deficiency of acid alpha-D-glucosidase,resulting from the mutations in the GAA gene. Measuring the level of enzyme activity and detection of the genomic mutations are the most accurate and definitive diagnostic method available at present.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2006年第12期962-965,共4页 Journal of Clinical Pediatrics
关键词 Ⅱ型糖原累积病 酸性α-葡萄糖苷酶 基因突变 glycogen storage disease type Ⅱ acid alpha-D-glucosidase genomic mutation
  • 相关文献

参考文献12

  • 1Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease:results of a phase Ⅱ clinical trial. Neuromuscul Disord,2005,15(1):24-31.
  • 2Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type Ⅱ by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther, 2005, 11 (6) : 889-898.
  • 3Salafsky IS, Nadler HL. Alpha-1, 4 glucosidase activity in Pompe's disease. J Pediatr, 1971,79(5) :794-798.
  • 4Ko TM, Hwu WL, Lin YW, et al. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat,1999,13(5) :380-384.
  • 5van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease:20 original cases compared with 133 cases from the literature. Pediatrics,2003,112(2) :332-340.
  • 6Laforet P, Nicolino M, Eymard B, et al. Juvenile and adultonset acid maltase deficiency in France:genotype- phenotype correlation. Neurology,2000,55 (8) : 1122-1128.
  • 7Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type Ⅱ in the Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet, 1999,7(6) :713-716.
  • 8Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type Ⅱ, Pompe disease). Curr Mol Med,2002,2(2) : 145-166.
  • 9Lin CY, Hwang B, Hsiao KJ, et al. Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity. J Inherit Metab Dis, 1987,10(1): 11-17.
  • 10Hermans MM,de Graaff E,Kroos MA,et al. The conservative substitution Asp- 645→Glu in lysosomal alpha - glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type Ⅱ. Biochem J, 1993,289(Pt 3):687-693.

同被引文献152

  • 1陈琳,郭玉璞,任海涛,赵燕环,关鸿志,管宇宙,彭斌,刘大为.少年起病的Ⅱ型糖原累积病五例临床病理研究[J].中华神经科杂志,2005,38(1):51-54. 被引量:16
  • 2单岩东,王朝东,张昆南.Ⅱ型糖原累积病的研究进展[J].中国临床神经科学,2007,15(2):203-207. 被引量:14
  • 3Hasan zen.Glycogen storage diseases: New perspectives[J].World Journal of Gastroenterology,2007,13(18):2541-2553. 被引量:33
  • 4KISHNANI P S, NICOLINO M, VOIT T. et al. Chinese hamster ovary cell-derived recombinant human acid alpha- glucosidase in infantile-onset Pompe disease [ J]. J Pediatr, 2006, 149 (1): 89-97.
  • 5VAN DEN HOUT J M, KAMPHOVEN J H, WINKEL L P, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk [J]. Pediatrics, 2004, 113 (5): e448-e457.
  • 6HUNLEY T E, CORZO D, DUDEK M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease [J]. Pediatrics, 2004, 114 (4) : e532-e535.
  • 7Richardson P,McKenna W,Bristow M,et al.Report of the 1995 World Health Organization International Society and Federation of Cardiology Task Force on the Defmition and Classification of Cardiomyopathies Circulation,1996,93:841-894.
  • 8Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Group; and Council on Epidemiology and Prevention.Circulation,2006,113:1807-1816.
  • 9Colan SD.Classification of the cardiomyopathies.Prog Pediatr Cardiol,2007,23:5-15.
  • 10Elliott P,Andersson B,Arbustini E,et al.Classification of the cardiomyopathies:a position statement from the European society of cardiology working group on myocardial and pericardial diseases.Eur Heart J,2008,29:270-276.

引证文献12

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部